Halozyme Therapeutics
HALO
eBay
EBAY
LIFE HEALTHCARE GROUP HOLDINGS UNSPON ADR EA REPR 4 ORD ZAR0.00
LTGHY
Teradata Corp
TDC
Hutchmed (China)
HCM
(Q2)Oct 31, 2024 | (Q2)Jun 30, 2024 | (FY)Apr 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 8,724.99%616.25M | 1,323.80%99.42M | 34.97%45.78M | 519.83%43.85M | -11.81%33.92M | 10.38M | -32.30%9.48M | -12.53%6.98M | -3.20%7.07M | 9.61%38.46M |
Operating revenue | 8,724.99%616.25M | 1,323.80%99.42M | 34.97%45.78M | 519.83%43.85M | -11.81%33.92M | --10.38M | -32.30%9.48M | -12.53%6.98M | -3.20%7.07M | 9.61%38.46M |
Cost of revenue | 465.51M | 40.81M | 0 | |||||||
Gross profit | 2,058.66%150.74M | 739.44%58.62M | 6.98M | |||||||
Operating expense | 2,129.28%86.27M | 696.74%30.83M | 86.02%29.75M | 613.84%27.23M | 13.90%15.99M | 5.34M | -3.67%2.96M | -0.18%3.87M | 2.97%3.82M | -18.49%14.04M |
Selling and administrative expenses | 1,886.61%76.88M | 641.45%28.69M | 89.06%29.7M | 637.88%27.19M | 24.09%15.71M | --5.32M | 3.93%2.93M | 9.88%3.87M | 15.44%3.69M | -3.17%12.66M |
-Selling and marketing expense | ---- | ---- | -2.17%1.71M | 1,293.75%1.34M | 43.64%1.75M | --890K | 30.14%367K | ---- | -80.25%96K | -62.39%1.22M |
-General and administrative expense | ---- | 641.45%28.69M | 100.50%27.99M | 620.34%25.85M | 22.01%13.96M | --4.43M | 1.02%2.57M | 17.13%3.87M | 32.63%3.59M | 16.34%11.44M |
Research and development costs | ---- | ---- | -83.63%46K | -67.69%42K | -79.64%281K | --22K | -88.19%30K | ---- | -74.66%130K | -66.75%1.38M |
Depreciation amortization depletion | --9.39M | --2.14M | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
-Depreciation and amortization | --9.39M | --2.14M | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Operating profit | 1,970.86%64.47M | 792.52%27.78M | -10.57%16.03M | 409.79%16.61M | -26.59%17.93M | 5.04M | -40.36%6.52M | -24.18%3.11M | -9.55%3.26M | 37.38%24.42M |
Net non-operating interest income expense | -114.90%-1.01M | -45.14%3.71M | -65.83%8.54M | 29.20%8.29M | 781.18%25.01M | 14.13M | -9.02%-2.38M | 215.22%6.76M | 193.46%6.42M | 658.82%2.84M |
Non-operating interest income | -47.63%3.54M | -31.81%4.61M | --8.84M | 29.20%8.29M | ---- | ---- | ---- | --6.76M | 193.46%6.42M | ---- |
Non-operating interest expense | --4.55M | --901K | --297K | ---- | ---- | ---- | 9.02%2.38M | --0 | ---- | ---- |
Total other finance cost | ---- | ---- | ---- | ---- | -781.18%-25.01M | ---- | ---- | ---- | ---- | ---2.84M |
Other net income (expense) | -59K | -2.38M | -263.96%-182K | 93.17%-20K | 125K | -5.52%-172K | 173.03%111K | 65.89%-293K | ||
Special income (charges) | ---59K | ---2.38M | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
-Less:Restructuring and merger&acquisition | --59K | --2.38M | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Other non- operating income (expenses) | ---- | ---- | ---- | -263.96%-182K | 93.17%-20K | --125K | -5.52%-172K | ---- | 173.03%111K | 65.89%-293K |
Income before tax | 542.22%63.4M | 194.91%29.11M | -42.73%24.58M | 152.63%24.72M | 59.15%42.92M | 19.29M | -53.80%3.97M | 595.33%9.87M | 73.59%9.79M | 55.96%26.97M |
Income tax | 168.67%7.64M | 187.55%8.18M | -23.94%6.8M | 302.46%6.07M | 341.66%8.94M | 3.3M | 46.52%1.29M | 1,734.48%2.84M | 168.63%1.51M | -176.97%-3.7M |
Net income | 693.38%55.76M | 311.85%28.95M | -47.68%17.78M | 125.36%18.66M | 10.80%33.98M | 15.99M | -65.22%2.68M | 486.37%7.03M | 63.08%8.28M | 145.63%30.66M |
Net income continuous Operations | 693.38%55.76M | 197.89%20.94M | -47.68%17.78M | 125.36%18.66M | 10.80%33.98M | --15.99M | -65.22%2.68M | 486.37%7.03M | 63.08%8.28M | 145.63%30.66M |
Net income discontinuous operations | ---- | --8.01M | ---- | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
Minority interest income | 28.6M | |||||||||
Net income attributable to the parent company | 286.41%27.16M | 311.85%28.95M | -47.68%17.78M | 125.36%18.66M | 10.80%33.98M | 15.99M | -65.22%2.68M | 486.37%7.03M | 63.08%8.28M | 145.63%30.66M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 286.41%27.16M | 311.85%28.95M | -47.68%17.78M | 125.36%18.66M | 10.80%33.98M | 15.99M | -65.22%2.68M | 486.37%7.03M | 63.08%8.28M | 145.63%30.66M |
Basic earnings per share | 281.82%0.84 | 313.64%0.91 | -46.67%0.56 | 140.00%0.6 | 14.13%1.05 | 0.49 | -65.22%0.08 | 540.00%0.22 | 66.67%0.25 | 130.00%0.92 |
Diluted earnings per share | 295.24%0.83 | 323.81%0.89 | -47.12%0.55 | 136.00%0.59 | 13.04%1.04 | 0.49 | -65.22%0.08 | 520.00%0.21 | 66.67%0.25 | 135.90%0.92 |
Dividend per share | 50.00%0.045 | 50.00%0.045 | 50.00%0.045 | 0.12 | 0.03 | 0.03 | 0.03 | 0.03 | ||
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | -- | -- | -- | -- | -- | -- | -- | -- | -- | Unqualified Opinion |